Novavax files COVID-19 vaccine data with FDA

Novavax on Friday filed final data with the Food and Drug Administration for its COVID-19 vaccine, clearing the way for a potential emergency approval next year.

The move was the last step for the Maryland-based biotechnology company to fulfill prerequisites for its protein-based vaccine, which is different than the other three vaccines approved in the U.S. from Pfizer, Moderna and Johnson & Johnson.

If all goes well, Novavax could seek emergency approval next month as the U.S. continues to prioritize booster shots amid a spike in confirmed coronavirus cases driven by the highly transmissible omicron variant.

"Novavax is committed to delivering our protein-based vaccine in the United States, where the COVID-19 pandemic continues to evolve with the emergence of new variants," Stanley Erck, the president and CEO of Novavax, said in a statement.

 

所有跟帖： 

• Novavax 的蛋白疫苗对 Omicron 病毒变体有效吗？有与 Omicron 变体相关的临床数据吗？ -Ron47- ♂ (0 bytes) () 01/02/2022 postreply 08:45:57